{"id":"W1989760088","doi":"10.1007/s00384-007-0395-7","title":"Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFα, improves health-related quality of life in patients with moderate to severe Crohn’s disease","year":2007,"lang":"en","type":"article","venue":"International Journal of Colorectal Disease","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":56,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; Robarts Clinical Trials","funders":"","keywords":"Certolizumab pegol; Medicine; Placebo; Internal medicine; Crohn's disease; Quality of life (healthcare); Inflammatory bowel disease; Gastroenterology; Infliximab; Disease; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005892077,0.000319228,0.0008338065,0.0001535879,0.0001114222,0.0002277141,0.0001575421,0.0003026437,0.0005853374],"category_scores_gemma":[0.0007634785,0.0001188032,0.000356788,0.0001476939,0.00023202,0.000137718,0.000114129,0.0004086884,0.0001028015],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001370493,"about_ca_system_score_gemma":0.0001726667,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001606043,"about_ca_topic_score_gemma":0.0004234722,"domain_scores_codex":[0.9998145,0.00009649411,0.00002026281,0.00001859402,0.00002517768,0.00002505696],"domain_scores_gemma":[0.9996296,0.0001162321,0.0001388735,0.00001328559,0.00001623592,0.00008579549],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.3389868,0.01929393,0.1479096,0.002807527,0.002988456,0.0009672173,0.0003604424,0.002567819,0.1372442,0.0001074792,0.002180459,0.3445862],"study_design_scores_gemma":[0.1214667,0.2940855,0.5596412,0.0001899869,0.001611063,0.002695718,0.0001828006,0.002522293,0.01302666,0.0002140162,0.004324955,0.00003903417],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963228,0.003073376,0.0001466127,0.0001037338,0.00002396507,0.00004968084,0.00003125658,0.00001607031,0.000232571],"genre_scores_gemma":[0.9983376,0.0008806092,0.0003737282,0.0001188187,0.00005490283,0.00003062585,0.0000839248,0.00000143852,0.000118357],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0008338065,"threshold_uncertainty_score":0.003116071,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008273711405574164,"score_gpt":0.2605176102723785,"score_spread":0.2522438988668043,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}